Análise da expressão e do papel da ADAM9 humana na capacidade invasiva de células tumorais por silenciamento gênico

• Ano de defesa: 2009
• Autor(a) principal: Micocci, Kelli Cristina
• Orientador(a): Araújo, Heloísa Sobreiro Selistre de
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de São Carlos
• Programa de Pós-Graduação: Programa Interinstitucional de Pós-Graduação em Ciências Fisiológicas - PIPGCF
• País: BR
• Palavras-chave em Português: Bioquímica; Mamas - câncer; RNA interferente; Fisiologia; ADAM9; Câncer e RNA de interferência (RNAi)
• Palavras-chave em Inglês: ADAM9; Cancer and interference RNA (iRNA)
• Área do conhecimento CNPq: CIENCIAS BIOLOGICAS::FISIOLOGIA
• Link de acesso: https://repositorio.ufscar.br/handle/20.500.14289/1319

ADAMs is a term used to describe the presence of disintegrin and metalloprotease domains(A Disintegrin And Metalloprotease) in a certain class of multi-functional membrane proteins,expressed in several animal species such as mammals and insects. They play important rolesin many physiological processes as in fertilization, myoblast fusion, migration, proliferationand cell survival, as well in diseases including breast, prostate, and pancreas cancer. ADAM9is involved in cellular processes such as adhesion, migration and signaling of tumor cells andit is involved in the metastatic spreading. Aims: To analyze the expression of ADAM9 intumor cell lines (MDA-MB-231 and DU-145), no tumors (FH and C2C12), and to generateknockout clones for ADAM9 expression using silencing RNA techniques for the study ofADAM9 effects on invasion, proliferation and gene expression of MDA-MB-231 cells.Methods: Cells were cultured and plated (2x106 cells/plate of 6cm) for 24 hours in DMEM(10% FBS) and lysed for western blotting and zymography. To check for inhibition ofadhesion to immobilized collagen I, MDA-MB-231 cells and FH (5x106 cells/ml) werelabeled with CMFDA, and then incubated with anti-ADAM9D and anti-RP3ADAM9 indifferent concentrations. For ADAM9 silencing, it was used a kit (Silencer ® siRNA StarterKit - Ambion), 2x105 cells (MDA-MB-231) and the transfection agent (Lipofectamine 2000 -Invitrogen). The cells were plated in 5ml of culture medium DMEM/plate. On the third daycells were treated with the transfection agent and RNA silencing primers. Total RNA wasisolated for RT-PCR, and proliferation and invasion in matrigel assays. Results: All the celllines studied expressed ADAM9 in the tested conditions. MMP-2 (Gelatinase-A) activity wasdetected in the cell extracts of all studied cell lines. Silencing of ADAM9 did not affect therate of MDA-MB-231 proliferation, at 4, 5, 6, 7, 8, 9 and 10 days after silencing (24 or 48hours of incubation in 96-well plates). Silencing of human ADAM9 inhibited tumor cellinvasion in matrigel (71,51±8,02%) when compared to control. Conclusion: The generation ofMDA-MB-231 knockout clones lacking ADAM9 expression using siRNA technique did notaffect the rate of cell proliferation but inhibited tumor cell matrigel invasion, suggesting thatADAM9 is an important molecule in the processes of invasion and metastasis.